Automate Your Wheel Strategy on KRYS
With Tiblio's Option Bot, you can configure your own wheel strategy including KRYS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KRYS
- Rev/Share 12.4249
- Book/Share 35.9961
- PB 4.9041
- Debt/Equity 0.0016
- CurrentRatio 9.6822
- ROIC 0.1282
- MktCap 5109304436.0
- FreeCF/Share 6.4145
- PFCF 27.5519
- PE 34.7826
- Debt/Assets 0.0014
- DivYield 0
- ROE 0.1521
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KRYS | Jefferies | -- | Buy | -- | $245 | March 5, 2025 |
News
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
KRYS
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023
Read More
About Krystal Biotech, Inc. (KRYS)
- IPO Date 2017-09-20
- Website https://www.krystalbio.com
- Industry Biotechnology
- CEO Krish S. Krishnan
- Employees 275
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.